These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Association between the CYP2C9 polymorphism and the drug metabolism phenotype. Topić E; Stefanović M; Samardzija M Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384 [TBL] [Abstract][Full Text] [Related]
6. Impact of CYP2C9 genetic polymorphism on warfarin dose requirements in Pakistani population. Siddiqi A; Khan DA; Khan FA; Naveed AK Pak J Pharm Sci; 2010 Oct; 23(4):417-22. PubMed ID: 20884456 [TBL] [Abstract][Full Text] [Related]
7. Relationship of S/R warfarin ratio with CYP2C9 genotypes in Pakistani population. Qayyum A; Najmi MH; Raza SI; Rajput TA; Naveed AK Pak J Pharm Sci; 2019 Jul; 32(4):1581-1588. PubMed ID: 31608877 [TBL] [Abstract][Full Text] [Related]
8. Analysis of CYP2C9 polymorphisms (*2 and *3) in warfarin therapy patients in Pakistan. Association of CYP2C9 polymorphisms (*2 and*3) with warfarin dose, age, PT and INR. Yasmeen F; Ghafoor MB; Khalid AW; Latif W; Mohsin S; Khaliq S J Thromb Thrombolysis; 2015 Aug; 40(2):218-24. PubMed ID: 25904339 [TBL] [Abstract][Full Text] [Related]
9. Association Between the Lower Extremity Deep Venous Thrombosis, the Warfarin Maintenance Dose, and CYP2C9*3, CYP2D6*10, and CYP3A5*3 Genetic Polymorphisms: A Case-Control Study. Ju S; Gao Y; Cao X; Zhang XF; Yan CC; Liu FT Genet Test Mol Biomarkers; 2017 Sep; 21(9):539-546. PubMed ID: 28872889 [TBL] [Abstract][Full Text] [Related]
10. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran. Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959 [TBL] [Abstract][Full Text] [Related]
11. Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome. Ghozlan MF; Foad DA; Darwish YW; Saad AA Blood Coagul Fibrinolysis; 2015 Jul; 26(5):499-504. PubMed ID: 25699611 [TBL] [Abstract][Full Text] [Related]
12. Quantitative Assessment of CYP2C9 Genetic Polymorphisms Effect on the Oral Clearance of S-Warfarin in Healthy Subjects. Shaul C; Blotnick S; Muszkat M; Bialer M; Caraco Y Mol Diagn Ther; 2017 Feb; 21(1):75-83. PubMed ID: 27878474 [TBL] [Abstract][Full Text] [Related]
13. Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen. El Din MS; Amin DG; Ragab SB; Ashour EE; Mohamed MH; Mohamed AM Int J Lab Hematol; 2012 Oct; 34(5):517-24. PubMed ID: 22533669 [TBL] [Abstract][Full Text] [Related]
14. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898 [TBL] [Abstract][Full Text] [Related]
15. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Miao L; Yang J; Huang C; Shen Z Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045 [TBL] [Abstract][Full Text] [Related]
16. Linkage disequilibrium between the CYP2C19*2,*17 and CYP2C9*1 alleles and impact of VKORC1, CYP2C9, CYP2C19 gene polymorphisms and gene-gene interactions on warfarin therapy. Khalighi K; Cheng G; Mirabbasi S; Khalighi B; Wu Y; Fan W J Thromb Thrombolysis; 2017 Jan; 43(1):124-129. PubMed ID: 27743182 [TBL] [Abstract][Full Text] [Related]
18. Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement. Chen W; Wu L; Liu X; Shen Y; Liang Y; Zhu J; Tan H; Yang Y; Liu Q; Wang M; Liu L; Wang X Int J Clin Pharmacol Ther; 2017 Feb; 55(2):126-132. PubMed ID: 27117036 [TBL] [Abstract][Full Text] [Related]
19. Warfarin maintenance dose associated with genetic polymorphisms of CYP2C9. Khaleqsefat E; Khalaj-Kondori M; Jabbarpour B; Battaloğlu E Hippokratia; 2017; 21(2):93-96. PubMed ID: 30455562 [TBL] [Abstract][Full Text] [Related]